Slack N H, Brady M F, Murphy G P
Cancer. 1984 Aug 1;54(3):564-74. doi: 10.1002/1097-0142(19840801)54:3<564::aid-cncr2820540330>3.0.co;2-6.
Stable response to therapy in patients with advanced prostate cancer, as experienced in clinical trials of the National Prostatic Cancer Project (NPCP) has been re-examined. Data from 10 completed trials, totaling over 1300 patients, have been examined for survival patterns within categories of response to therapy. Survival patterns, for patients alive at 12 weeks, were significantly poorer for patients who were categorized as progressors after 12 weeks on treatment than for those who were categorized as stable or as partial regressions. Furthermore, comparisons of survival patterns for those patients who were categorized as stable or partial regression revealed no statistically significant differences between them. The concerns over the use of stable as an indicator of response and the problems in establishing its true meaning are discussed. All things considered, the use of stable is a valid means to evaluate the status of patients in clinical trials of treatment modalities for advanced cancer of the prostate.
对国家前列腺癌项目（NPCP）临床试验中晚期前列腺癌患者对治疗的稳定反应进行了重新审视。对10项已完成试验的数据（总计超过1300名患者）进行了检查，以了解治疗反应类别中的生存模式。对于治疗12周时仍存活的患者，在治疗12周后被归类为病情进展者的生存模式明显比被归类为病情稳定或部分缓解者更差。此外，对被归类为病情稳定或部分缓解的患者的生存模式进行比较，结果显示两者之间无统计学显著差异。文中讨论了对将病情稳定用作反应指标的担忧以及确定其真正含义时存在的问题。综合考虑，病情稳定的使用是评估晚期前列腺癌治疗方式临床试验中患者状况的有效手段。
